Semaglutide Side Effects: Complete Guide to Managing Symptoms

Semaglutide is highly effective for weight loss and type 2 diabetes — but as with any medication that produces meaningful biological change, it comes with side effects. Most are manageable. A few are serious. Understanding which is which — and what to do about each — is the difference between a frustrating treatment experience and a successful one.

This guide covers every notable semaglutide side effect, the clinical evidence behind it, and practical management strategies that work in real-world patient experience. It is YMYL content; every medical claim is sourced. If you're experiencing severe symptoms now and need urgent guidance, contact your prescriber or a 24/7 nurse line — this article is education, not medical advice.

For a broader picture of the medication itself, see our semaglutide drug guide. For dose-by-dose expectations, read our semaglutide dosing schedule.

Key Takeaways

• 80% of patients experience some GI side effect at some point during titration; most are mild.
• Nausea is the most common and almost always improves within 2 weeks of each dose increase.
• Constipation is more under-reported than nausea but easier to manage with hydration and fiber.
• Pancreatitis and gallbladder disease are rare but serious — know the warning signs.
• Slow titration is the single most effective prevention strategy for almost every side effect.
• Discontinuation due to side effects in the STEP-1 trial was 4.5%, lower than most lifestyle interventions.

The Most Common Side Effects (and How to Manage Them)

Nausea

The single most common semaglutide side effect, reported by ~44% of patients in STEP-1. It usually peaks 24–72 hours after an injection — especially after a dose increase — and improves as your body acclimates over the following 1–2 weeks.

Why it happens: Semaglutide slows the rate at which your stomach empties. A stomach that holds food longer makes you feel full, which serves weight loss well. The same sensation slides into nausea easily enough, and a large or fatty meal is usually what slides it.

Management:

• Eat smaller, more frequent meals (4–6 small meals instead of 3 large ones)
• Avoid greasy, fried, or very high-fat foods on injection day and the day after
• Slow down — chewing thoroughly is more important on semaglutide than off it
• Stay hydrated; sip clear fluids throughout the day
• Ginger (real ginger, ginger tea, or ginger chews) is mildly effective
• If symptoms are severe, your prescriber can prescribe ondansetron (Zofran) or promethazine — common interventions in the GLP-1 telehealth space

When to call your prescriber: Nausea that prevents you from staying hydrated, vomiting more than twice a week, weight loss faster than 2.5 lb/week consistently, or any sign of dehydration (dark urine, dizziness, fatigue beyond normal).

Constipation

Reported by ~24% of STEP-1 patients but probably under-reported. Constipation is common, and it comes from two directions at once — the stomach empties more slowly and there is less food going in.

Management:

• Increase water intake significantly (aim for 80+ oz per day)
• Add fiber gradually (psyllium husk, ground flaxseed, vegetables)
• Magnesium citrate (200–400 mg at bedtime) is well-tolerated and effective
• Walk or move daily — physical activity helps GI motility
• If constipation persists more than 5 days, discuss laxatives with your prescriber

Vomiting

Reported by ~24% of patients in STEP-1. Usually associated with eating too much, eating too fast, or eating high-fat foods after a recent injection.

Management:

• Put the fork down the moment fullness registers. This takes practice, because semaglutide changes what fullness feels like
• Leave alcohol alone, above all in the 48 hours following an injection
• On injection day, skip anything fried, fatty or heavily spiced
• Sit upright for 30+ minutes after meals
• If vomiting is frequent (>2x/week), ask your prescriber to slow your titration or hold your current dose

Diarrhea

Reported by ~30% of STEP-1 patients. Usually mild and self-limiting.

Management:

• Stay hydrated (electrolyte beverages, broth, oral rehydration solutions)
• Avoid dairy, caffeine, and high-sugar foods until symptoms resolve
• The BRAT diet (bananas, rice, applesauce, toast) is gentle
• If diarrhea persists more than 3 days or is bloody, contact your prescriber

Fatigue

Less discussed than GI symptoms but commonly reported by patients in real-world surveys. Three causes account for most of it: dehydration, a large drop in calories because you are simply eating less, or low blood sugar — the last especially where insulin or sulfonylureas are also in play.

Management:

• Make sure you're hitting your protein target (0.8–1.0 g per pound of goal body weight)
• Stay hydrated
• If you're diabetic and on other glucose-lowering medications, discuss with your prescriber whether dosages need adjustment
• Sleep 7–9 hours per night
• Light exercise (walking) helps fatigue counterintuitively

Headache

Reported by ~14% of STEP-1 patients. Often associated with dehydration or low blood sugar.

Management:

• Hydration first
• Eat regularly even when not hungry
• Standard OTC pain relievers (acetaminophen, ibuprofen) are fine for occasional use

Less Common but Important Side Effects

Injection site reactions

Itching, swelling or mild redness where you injected is common, and it settles without treatment. Rotate injection sites (abdomen, thigh, upper arm) and avoid injecting through clothing.

Hair thinning

Some patients report hair shedding during rapid weight loss on semaglutide. This is usually due to telogen effluvium (a stress response to rapid weight loss, not a direct drug effect). It typically resolves within 6–12 months. Adequate protein and biotin intake may help.

Mood changes

The FDA has investigated reports of suicidal ideation in GLP-1 patients but has not found a causal link. Still, if you experience new depression or anxiety while on semaglutide, discuss with your prescriber.

Hypoglycemia

Low blood sugar is rare in non-diabetic patients on semaglutide. It's more common in diabetes patients also taking insulin or sulfonylureas, where dose adjustments may be needed.

Serious (Rare) Side Effects — Know the Warning Signs

These are uncommon but require immediate medical attention.

Pancreatitis

The FDA has flagged pancreatitis as a potential risk for all GLP-1 drugs, though large observational studies in 2023–2024 have shown the absolute risk is small. A 2024 JAMA Internal Medicine study put the incidence at roughly 0.1–0.2% in GLP-1 users, modestly elevated above baseline.

Warning signs:

• Severe abdominal pain that radiates to the back
• Pain that worsens after eating
• Nausea and vomiting that doesn't resolve
• Fever, rapid pulse

What to do: Stop the medication and seek immediate medical evaluation.

Gallbladder disease

Rapid weight loss of any kind (not just GLP-1-induced) increases the risk of gallstones and gallbladder inflammation. STEP-1 reported gallbladder-related events in about 2.6% of semaglutide patients vs 1.2% of placebo over 68 weeks.

Warning signs:

• Sharp pain high on the right of the abdomen, typically after a fatty meal
• That pain reaching through into the back, or the right shoulder
• Nausea, vomiting, fever
• Yellowing of skin or eyes (jaundice — this is urgent)

What to do: Contact your prescriber. Many patients can continue semaglutide after gallbladder evaluation; some require surgical intervention.

Acute kidney injury

Severe dehydration from prolonged nausea and vomiting can cause acute kidney injury. Preventable, mostly. Keep your fluids up, and call your prescriber the moment you cannot keep them down.

Thyroid C-cell tumors

Semaglutide's boxed warning rests on rodent studies, and concerns thyroid C-cell tumors. No human data has confirmed that risk. The contraindication stands regardless. It is triggered by either of two histories, the patient's own or a relative's — MEN2, that is multiple endocrine neoplasia syndrome type 2, and MTC, medullary thyroid carcinoma.

Diabetic retinopathy complications

In patients with pre-existing diabetic retinopathy, rapid improvement in blood sugar from semaglutide can paradoxically worsen retinal disease in the short term. If you have diabetes and any history of eye disease, see an ophthalmologist before starting and during treatment.

Side Effects by Dose

In STEP-1, the percentage of patients reporting each common side effect at the 2.4 mg maintenance dose:

Most symptoms were rated as mild to moderate. Only 4.5% of semaglutide patients discontinued due to adverse events vs 0.8% on placebo.

Slow Titration Is the Best Prevention

Every study and every clinician interview confirms the same finding: slow titration prevents most side effects. The standard 4-weeks-per-dose schedule exists for a reason. If you're struggling, ask your prescriber about extending each dose level to 6 or even 8 weeks. There is no medal for finishing titration on schedule.

Reputable GLP-1 telehealth providers make it easy to message your prescriber and request a dose hold or step-back. This is one of the most underrated features when comparing providers — see our methodology for how we evaluate each provider's clinical responsiveness.

For a complete week-by-week guide to what to expect at each dose level, read our semaglutide dosing schedule.

When to Stop the Medication

Most side effects can be managed with patience, hydration, dietary adjustments, and dose modifications. But there are situations where stopping semaglutide is the right call:

• Confirmed pancreatitis
• Severe gallbladder disease requiring surgery
• Severe allergic reaction (rash, swelling, breathing difficulty)
• Pregnancy (semaglutide is contraindicated; discontinue at least 2 months before conception)
• Persistent inability to maintain adequate nutrition
• New diagnosis of medullary thyroid carcinoma or MEN2 in you or a first-degree relative

If you stop semaglutide, the appetite-suppressing effect wears off within a few weeks. In STEP-4, stopping at a year cost patients about two-thirds of what they had lost, over the twelve months that followed. If you need to stop temporarily for a medical issue, talk to your prescriber about restarting at a lower dose to avoid re-experiencing initial titration symptoms.

Bottom Line

Most semaglutide side effects are mild, predictable, and manageable. Nausea and constipation are the big two; both respond well to dietary adjustments, hydration, and dose pacing. The serious side effects (pancreatitis, gallbladder disease, kidney injury) are rare but real, and patients should know the warning signs.

Two habits matter more than anything else for keeping side effects down: climb the dose slowly, and tell your prescriber what is actually happening. If you're working with a reputable telehealth provider, this is straightforward. If your provider doesn't make it easy to message a prescriber and request dose changes, that's a red flag — see our compounded semaglutide safety guide for more on choosing a provider with real medical oversight.

For more on the underlying drug, see our semaglutide drug guide. For the head-to-head with tirzepatide (which has a similar but slightly different side effect profile), read Semaglutide vs Tirzepatide.